Tab%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520linagliptin

# Tradjenta (linagliptin) ## Overview Linagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used for the management of type 2 diabetes mellitus. It works by increasing incretin levels, which in turn reduces fasting and postprandial glucose concentrations. ## Primary Indications * Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. * Can be used as monotherapy or in combination with other oral antidiabetic agents (e.g., metformin, sulfonylureas, thiazolidinediones) or insulin. ## Adult Dosing The recommended dose is **5 mg orally once daily**. Linagliptin can be taken with or without food. ## Pediatric Dosing Dosing for pediatric patients has not been established. ## Dose Adjustments No dose adjustment is required for patients with mild, moderate, or severe renal impairment or for patients with end-stage renal disease requiring dialysis. No dose adjustment is required for patients with hepatic impairment. ## Contraindications * Hypersensitivity to linagliptin or any excipient in the formulation. ## Adverse Effects Commonly reported adverse effects include: * Hypoglycemia (especially when used in combination with sulfonylureas or insulin) * Diarrhea * Nasopharyngitis Less common but serious adverse effects include: * Pancreatitis * Severe and disabling arthralgia (joint pain) * Bullous pemphigoid ## Key Drug Interactions * **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort):** May decrease linagliptin exposure and efficacy. Coadministration with strong CYP3A4 inducers is not recommended. * **Other Antidiabetic Agents:** Increased risk of hypoglycemia when used with sulfonylureas or insulin. ## Monitoring * **Glycemic control:** Monitor HbA1c and fasting blood glucose levels. * **Signs and symptoms of pancreatitis:** Assess for persistent severe abdominal pain. * **Signs and symptoms of arthralgia:** Assess for severe joint pain. * **Signs and symptoms of bullous pemphigoid:** Assess for skin blistering. ## Clinical Pearls * Linagliptin does not require dose adjustment based on renal or hepatic function, making it a convenient option for patients with impaired organ function. * Due to the lack of renally dependent dosing, it may be preferred in patients with higher risk or degree of renal impairment. * The risk of hypoglycemia is dose-dependent when linagliptin is added to medications with a known risk of hypoglycemia, such as sulfonylureas or insulin. * Advise patients to report any severe, persistent abdominal pain, as this may be a sign of pancreatitis. *** *Disclaimer: This information is intended for healthcare professionals and does not replace the need to consult the most current prescribing information and relevant guidelines.*